Speaker Profile

Ph.D., CEO, BillionToOne Inc.

At BillionToOne, Oguzhan co-developed a molecular counter platform that increases the resolution of cell-free DNA diagnostics by over a thousandfold. This technology was used to develop BillionToOne’s single-gene NIPT, which is the only (and fastest-growing) test that can detect the most common inherited disorders such as sickle cell disease, cystic fibrosis, and spinal muscular atrophy in the fetus directly from maternal blood. Oguzhan led BillionToOne through Y Combinator and raised a total of more than $90M in funding including from venture capital funds and investors who previously invested in companies such as SpaceX, Uber, Box, Spotify, Palantir, Braintree, WebMD, and Omada Health. Previously, Oguzhan received his PhD from Stanford, where his work was published on the Cover of Cell Systems, and graduated summa cum laude and Phi Beta Kappa from Princeton University with a Bachelor’s in Molecular Biology and minors in Physics, Computer Science, and Applied Mathematics.

Clinical Dx Showcase:
BillionToOne Inc.

BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more powerful, accurate, and accessible for all. Our QCT molecular counting platform enables us to offer unique products from single-gene NIPT to quantitative liquid biopsy for treatment monitoring.

Molecular Counting Enables High-resolution Liquid Biopsy Panel for Cancer Treatment Monitoring
We describe a novel pan-cancer liquid biopsy panel that quantifies the changes in cell-free tumor DNA level at the single-molecule resolution in cancer patients, without the need to customize the panel.

 Session Abstract – PMWC 2022 Silicon Valley

The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative